The HERA study is a clinical trial for the investigational drug RG-012. HERA is a Phase II study designed to evaluate the safety and effectiveness of RG-012 compared to placebo in patients with Alport syndrome.
In the HERA study, eligible Alport syndrome participants will be assigned to receive the investigational drug RG-012 or placebo. The study treatment will be assigned randomly (like flipping a coin) with two-thirds of the participants assigned to RG-012 (either 110 mg or 220 mg) and the other one-third to placebo. Neither the participant nor the doctor will know what study treatment has been assigned. Both RG-012 and placebo will be given as a weekly injection for 24 weeks. Travel and lodging assistance is available as well as in-home visits.
Participants that complete the 24 weeks may be eligible to continue in another clinical trial called the extension study. All participants will receive RG-012 during the extension study even if they were taking placebo during the HERA study.
Contact a location near you to learn about the HERA study if you:
You are not qualified for this study if you:
To locate your nearest study center, please use the site locator. The study team will contact you to review the study requirements and discuss whether you may be eligible to participate.